- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06147635
Prophylactic Tributyrin Supplementation in Acute Pancreatitis (PARROT)
Prophylactic Tributyrin Supplementation in Acute Pancreatitis; a Phase IIa (Proof of Concept) Double-blind Randomized Placebo-controlled Food Supplement Trial
The goal of this clinical trial is to investigate the possible effects of tributyrin supplementation in patients with a first episode of acute pancreatitis. The main question it aims to answer is:
• The effect of oral tributyrin supplementation on the plasma endotoxin level
Participants will be randomized between two groups: intervention and control group. They will receive:
- three times daily 4grams of micro-encapsulated granules of tributyrin, and the control group three times daily 4 grams of micro-encapsulated sunflower oil (i.e. placebo), for a total of 14 days
In total 92 adult patients with a first episode of acute pancreatitis will be included.
Study Overview
Status
Conditions
Detailed Description
Rationale: Acute pancreatitis (AP) is a common gastrointestinal disorder requiring acute hospitalization. Around 20% of patients that present with acute pancreatitis eventually develop severe complications such as (multiple) organ failure, (peri-) pancreatic necrosis, and secondary infections (i.e. infected necrosis, bacteraemia, pneumonia). The gut, especially the gut microbiome, is likely to play a role in development of infectious complications. Short-chain fatty acids (SCFAs) produced by the gut microbiota, such as butyrate, are known immunomodulators of the host response and exert local beneficial effects on the gut barrier and microbiota. Currently, there are no safe and effective therapies to mitigate disease severity that can be administered in the early phase of pancreatitis. We hypothesize that orally administered tributyrin, a pro-drug of butyrate, might beneficially influence disease progression in acute pancreatitis and may be useful as prophylaxis.
Objective: The main objective is to investigate the effect of oral tributyrin on plasma endotoxin in patients with acute pancreatitis after 3 days of treatment.
Study design: Phase IIa (Proof of concept) double-blind randomized placebo-controlled food supplement trial.
Study population: 92 adult patients with a first episode of acute pancreatitis.
Intervention: The intervention group receives three times daily 4g micro-encapsulated granules of tributyrin and the control group receives three times daily an equivalent volume of micro-encapsulated vegetable oil (i.e. placebo), for a total of maximum 14 days.
Main study parameters/endpoints: The primary endpoint is plasma endotoxin concentration after 3 days of tributyrin treatment. Secondary endpoints include toxicity, clinical outcomes, intestinal permeability, fecal SCFA concentrations, intestinal microbiota composition and systemic inflammatory response parameters (pulse, respiratory rate, temperature and white blood cell count).
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The blood sampling at inclusion, and day 3 and 7 of treatment are preferably combined with regular blood sampling. Participants may experience minor discomfort from rectal swabs. Phase 1 studies with oral tributyrin conducted in patients with solid tumors did not report serious adverse events. However, there is a risk of unanticipated adverse events in our target population. An independent data safety and monitoring board (DSMB) will discuss all reported serious adverse events (SAE's).
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Hannah Pauw, MD
- Phone Number: +31 0883207051
- Email: ha.pauw@antoniusziekenhuis.nl
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- First episode of acute pancreatitis (AP)
- Able to read and/or understand the study procedures
- Able to give informed consent (or their legal representatives)
- <24 hours after diagnosis of AP
- <72 hours after onset of symptoms of AP
Exclusion Criteria:
- Pancreatitis due to endoscopic retrograde cholangiopancreatography (ERCP), malignancy or trauma
- Post-operative pancreatitis
- Intra-operative diagnosis
- Immunocompromised patients (history or current immunosuppressive treatment such as chemotherapy, radiotherapy, longer use of immunosuppressive medication or recent high doses, immunocompromised illness' such as AIDS, leukemia, lymphoma)
- Pregnancy and/or lactation
- Age <18 years old
- History of recurrent or chronic (MANNHEIM criteria25) pancreatitis (see Appendix 15.1 for definition)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention group
Micro-encapsulated tributyrin granules, 4 grams three times daily, for a maximum of 14 days
|
Three times daily 4 grams of micro-encapsulated granules of tributyrin, for a maximum of 14 days
|
Placebo Comparator: Control group
Micro-encapsulated sunflower oil granules, 4 grams three times daily, for a maximum of 14 days
|
Three times daily 4 grams of micro-encapsulated granules of sunflower oil, for a maximum of 14 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma endotoxin levels
Time Frame: Measured 3 days after randomisation
|
Plasma endotoxin levels
|
Measured 3 days after randomisation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality
Time Frame: During the whole study period including follow-up of 90 days
|
Occurence of death
|
During the whole study period including follow-up of 90 days
|
Infectious complications
Time Frame: During the whole study period including follow-up of 90 days
|
The occurence of infected pancreatic necrosis, bacteremia, pneumonia, urosepsis, and/or infected ascites
|
During the whole study period including follow-up of 90 days
|
(New onset) transient/persistant (multiple) organ failure
Time Frame: During the whole study period including follow-up of 90 days
|
The occurence of (new onset) transient/persistant (multiple) organ failure
|
During the whole study period including follow-up of 90 days
|
Disease severity according to the revised Atlanta Classification
Time Frame: During the whole study period including follow-up of 90 days
|
Disease severity according to the revised Atlanta Classification
|
During the whole study period including follow-up of 90 days
|
(Peri-)pancreatic necrosis
Time Frame: During the whole study period including follow-up of 90 days
|
The occurence of (peri)pancreatic necrosis
|
During the whole study period including follow-up of 90 days
|
Length of hospital and/or ICU stay
Time Frame: During the whole study period including follow-up of 90 days
|
Measured in days
|
During the whole study period including follow-up of 90 days
|
The need (and number of) for surgical, endoscopic or radiologic interventions
Time Frame: During the whole study period including follow-up of 90 days
|
The need (and number of) for surgical, endoscopic or radiologic interventions
|
During the whole study period including follow-up of 90 days
|
Fecal and saliva microbiota and fecal metabolomics (i.e., SCFAs) analysis
Time Frame: During the whole study period including follow-up of 90 days
|
Fecal and saliva microbiota and fecal metabolomics (i.e., SCFAs) analysis
|
During the whole study period including follow-up of 90 days
|
Readmissions
Time Frame: During the whole study period including follow-up of 90 days
|
The occurrence and number of readmissions
|
During the whole study period including follow-up of 90 days
|
Systemic inflammatory response parameters (SIRS): pulse
Time Frame: During the initial admission
|
Pulse measured in beats per minute
|
During the initial admission
|
Systemic inflammatory response parameters (SIRS): respiratory rate
Time Frame: During the initial admission
|
Respiratory rate measured in breaths per minute
|
During the initial admission
|
Systemic inflammatory response parameters (SIRS): temperature
Time Frame: During the initial admission
|
Temperature measured in degrees celsius
|
During the initial admission
|
Systemic inflammatory response parameters (SIRS): white blood cell count
Time Frame: During the initial admission
|
White blood cell count
|
During the initial admission
|
Exocrine insufficiency
Time Frame: During the whole study period including follow-up of 90 days
|
Exocrine insufficiency
|
During the whole study period including follow-up of 90 days
|
Endocrine insufficiency
Time Frame: During the whole study period including follow-up of 90 days
|
Endocrine insufficiency
|
During the whole study period including follow-up of 90 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: H. C. van Santvoort, dr. prof., St. Antonius Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL81496.100.22
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Pancreatitis
-
Centre Hospitalier Universitaire de NiceRecruiting
-
John Gasdal KarstensenCompleted
-
Tianjin Nankai HospitalCompletedAcute PancreatitisChina
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedAcute Pancreatitis (AP) | Gallstone Pancreatitis | Alcoholic Pancreatitis | Trauma Acute Pancreatitis | Hypertriglyceridemia Acute Pancreatitis | Idiopathic (Unknown) Acute Pancreatitis | Medication Induced Acute Pancreatitis | Cancer Acute Pancreatitis | Miscellaneous (i.e. Acute on Chronic Pancreatitis)United States
-
Northern State Medical UniversityCompleted
-
Erzhen ChenRenJi HospitalUnknownPancreatitis,Acute NecrotizingChina
-
Orlando Health, Inc.Mayo Clinic; University of Alabama at Birmingham; University of Southern California and other collaboratorsActive, not recruitingPancreatitis,Acute NecrotizingUnited States
-
University of OuluCopenhagen University Hospital, HvidovreUnknownAcute Necrotizing PancreatitisFinland
-
Sichuan Academy of Medical SciencesPeking Union Medical College HospitalCompleted
-
Interscope, Inc.CompletedAcute Pancreatitis | Necrotizing Pancreatitis | Acute Pancreatic NecrosisUnited States, Netherlands, Germany
Clinical Trials on Micro-encapsulated granules of tributyrin (intervention)
-
RenJi HospitalShanghai Institute of Biochemistry and Cell BiologyNot yet recruitingAcute-On-Chronic Liver Failure | Chronic Liver Failure
-
Bausch Health Americas, Inc.CompletedUlcerative ColitisUnited States
-
University of NebraskaMayo Clinic; Astellas Pharma IncCompletedCoronary Artery Disease | Myocardial Perfusion AbnormalitiesUnited States
-
University of L'AquilaCompletedMaxillary Sinus Floor Augmentation
-
National Cancer Institute (NCI)SuspendedClinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous MelanomaUnited States
-
Julio RamirezUniversity of LouisvilleTerminatedOsteomyelitisUnited States